Further developments in pharmacotherapy for the simultaneous treatment of prediabetes associated with overweight may also derive from the promising results of early studies on the use of new incretin receptor coagonists with combined action on GLP-1, GIP, and/or glucagon receptors, which have shown greater efficacy in glycemic control and weight loss compared to selective agonists. The gene discussed is GIP; the disease is prediabetes syndrome.